Literature DB >> 1370431

Myosin-cross-reactive epitope of Shigella flexneri invasion plasmid antigen B.

E V Oaks1, K R Turbyfill.   

Abstract

IpaB, invasion plasmid antigen B, of Shigella flexneri is a 62-kDa protein required for invasion of intestinal epithelial cells. IpaB is also one of several major protein antigens recognized by the humoral immune systems of most humans and monkeys after infection with shigellae. Computer analysis of the deduced IpaB amino acid sequence indicates that an alpha-helical structure is likely through much of the molecule. Homology searches with protein data banks show that one alpha-helical domain between amino acid residues 95 and 181 has a moderate level of identity with myosin and streptococcal M protein. By using a monoclonal antibody (2F1) which recognizes an epitope in the amino-terminal third of the IpaB protein, it was possible to demonstrate a cross-reactive epitope(s) on skeletal muscle myosin. Epitope mapping localized the 2F1 epitope to three noncontiguous regions of the IpaB protein within the alpha-helical domain that contains homology with myosin. Antibodies produced in rabbits immunized with synthetic peptides from one of the 2F1 epitope regions (residues 99 to 110) of IpaB were capable of reacting with IpaB as well as myosin. Furthermore, sera from several monkeys previously infected with S. flexneri 2a contained antibodies to IpaB pep 101-116 (IpaB peptide 101-116) and also myosin. Sera from animals with antibodies against other IpaB peptides did not contain antibodies against myosin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370431      PMCID: PMC257664          DOI: 10.1128/iai.60.2.557-564.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  Characterization of invasion plasmid antigen genes (ipaBCD) from Shigella flexneri.

Authors:  M M Venkatesan; J M Buysse; D J Kopecko
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

2.  Molecular evolution of streptococcal M protein: cloning and nucleotide sequence of the type 24 M protein gene and relation to other genes of Streptococcus pyogenes.

Authors:  A R Mouw; E H Beachey; V Burdett
Journal:  J Bacteriol       Date:  1988-02       Impact factor: 3.490

3.  A genetic determinant required for continuous reinfection of adjacent cells on large plasmid in S. flexneri 2a.

Authors:  S Makino; C Sasakawa; K Kamata; T Kurata; M Yoshikawa
Journal:  Cell       Date:  1986-08-15       Impact factor: 41.582

Review 4.  Myosin structure and function in cell motility.

Authors:  H M Warrick; J A Spudich
Journal:  Annu Rev Cell Biol       Date:  1987

5.  Entry of Shigella flexneri into HeLa cells: evidence for directed phagocytosis involving actin polymerization and myosin accumulation.

Authors:  P Clerc; P J Sansonetti
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

6.  Reaction of anti-HLA-B monoclonal antibodies with envelope proteins of Shigella species. Evidence for molecular mimicry in the spondyloarthropathies.

Authors:  R B Raybourne; V K Bunning; K M Williams
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

7.  Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei.

Authors:  S B Formal; E V Oaks; R E Olsen; M Wingfield-Eggleston; P J Snoy; J P Cogan
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

8.  Molecular cloning of invasion plasmid antigen (ipa) genes from Shigella flexneri: analysis of ipa gene products and genetic mapping.

Authors:  J M Buysse; C K Stover; E V Oaks; M Venkatesan; D J Kopecko
Journal:  J Bacteriol       Date:  1987-06       Impact factor: 3.490

9.  Development and testing of invasion-associated DNA probes for detection of Shigella spp. and enteroinvasive Escherichia coli.

Authors:  M Venkatesan; J M Buysse; E Vandendries; D J Kopecko
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

10.  Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp.

Authors:  E V Oaks; T L Hale; S B Formal
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

View more
  6 in total

1.  Characterization of B-cell epitopes on IpaB, an invasion-associated antigen of Shigella flexneri: identification of an immunodominant domain recognized during natural infection.

Authors:  S Barzu; F Nato; S Rouyre; J C Mazie; P Sansonetti; A Phalipon
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

2.  Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a.

Authors:  K R Turbyfill; S W Joseph; E V Oaks
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

3.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

4.  Efficient production of immunologically active Shigella invasion plasmid antigens IpaB and IpaH using a cell-free expression system.

Authors:  Neeraj Kapoor; Esther Ndungo; Lucy Pill; Girmay Desalegn; Aym Berges; Edwin V Oaks; Jeff Fairman; Marcela F Pasetti
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-21       Impact factor: 4.813

5.  Genome sequencing of multidrug resistant novel Clostridium sp. BL8 reveals its potential for pathogenicity.

Authors:  Nachiket Prakash Marathe; Sudarshan Anand Shetty; Vikram B Lanjekar; Mandar Hemant Rasane; Dilip R Ranade; Yogesh S Shouche
Journal:  Gut Pathog       Date:  2014-07-18       Impact factor: 4.181

6.  Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex.

Authors:  K Ross Turbyfill; Kristen A Clarkson; Anthony R Vortherms; Edwin V Oaks; Robert W Kaminski
Journal:  mSphere       Date:  2018-03-28       Impact factor: 4.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.